glp 1 ankylosing spondylitis GLP-1 Drugs: For Multiple Chronic Conditions 16 Effects of Ankylosing Spondylitis

J Periodontal Res (2021) 56:9911005

Pharmacy 7(3):127 Hughes RA (2002) Peripheral neuropathy

Craig Koniver suggests its currently showing some similar clinical results to BPC-157 results

In March 2024, Viking Therapeutics announced positive results from the company's Phase I multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735 , a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, in development for the potential treatment of metabolic disorders such as obesity

The identification of this protein sparked interest among researchers, who began to explore its potential therapeutic applications beyond the gastrointestinal system